Zobrazeno 1 - 10
of 247
pro vyhledávání: '"Daniel M Geynisman"'
Autor:
Matthew Zibelman, Alexander W. MacFarlane, Kimberly Costello, Thomas McGowan, John O’Neill, Rutika Kokate, Hossein Borghaei, Crystal S. Denlinger, Efrat Dotan, Daniel M. Geynisman, Angela Jain, Lainie Martin, Elias Obeid, Karthik Devarajan, Karen Ruth, R. Katherine Alpaugh, Essel Al-Saleem Dulaimi, Edna Cukierman, Margret Einarson, Kerry S. Campbell, Elizabeth R. Plimack
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-11 (2023)
Abstract This phase I, dose-escalation trial evaluates the safety of combining interferon-gamma (IFN-γ) and nivolumab in patients with metastatic solid tumors. Twenty-six patients are treated in four cohorts assessing increasing doses of IFN-γ with
Externí odkaz:
https://doaj.org/article/ce3d085e03764e52a9561fa23ca9cb9a
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 15 (2023)
Immunotherapy has proven effective in metastatic renal cell carcinoma (RCC). The current standard of treatment in localized RCC is partial or complete nephrectomy. However, after surgery, there is a high recurrence rate and survival rates ranging fro
Externí odkaz:
https://doaj.org/article/b3f6e85f8a604064b868afe3d710bc73
Autor:
David Strauss, Briana Kaplunov, Alexander Kutikov, Daniel M. Geynisman, Kwan Lau, Marc Smaldone
Publikováno v:
Urology Case Reports, Vol 48, Iss , Pp 102399- (2023)
Multimodal immunosuppression is the backbone of modern solid organ transplantation. However, immunosuppression itself is an independent risk factor for post-transplant malignancy. Although skin malignancy is the most common post-transplant malignancy
Externí odkaz:
https://doaj.org/article/d482417af8334470b4cb654a03280aa9
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 13 (2021)
The standard treatment for non-metastatic muscle-invasive bladder cancer (MIBC) is cisplatin-based neoadjuvant chemotherapy followed by radical cystectomy or trimodality therapy with chemoradiation in select patients. Pathologic complete response (pC
Externí odkaz:
https://doaj.org/article/24dc6d78162848f2b408d4617d558ac2
Autor:
Noah M. Hahn, Michael A. O'Donnell, Jason A. Efstathiou, Marianna Zahurak, Gary L. Rosner, Jeff Smith, Max R. Kates, Trinity J. Bivalacqua, Phuoc T. Tran, Daniel Y. Song, Alex S. Baras, Andres Matoso, Woonyoung Choi, Kellie N. Smith, Drew M. Pardoll, Luigi Marchionni, Bridget McGuire, Mary Grace Phelan, Burles A. Johnson, Tanya O'Neal, David J. McConkey, Tracy L. Rose, Marc Bjurlin, Emerson A. Lim, Charles G. Drake, James M. McKiernan, Israel Deutsch, Christopher B. Anderson, Donald L. Lamm, Daniel M. Geynisman, Elizabeth R. Plimack, Mark A. Hallman, Eric M. Horwitz, Essel Al-Saleem, David Y.T. Chen, Richard E. Greenberg, Alexander Kutikov, Gordon Guo, Timothy A. Masterson, Nabil Adra, Hristos Z. Kaimakliotis
Publikováno v:
European Urology. 83:486-494
Autor:
H. Josh Jang, Galen Hostetter, Alexander W. Macfarlane, Zachary Madaj, Eric A. Ross, Toshinori Hinoue, Justin R. Kulchycki, Ryan S. Burgos, Mahvish Tafseer, R. Katherine Alpaugh, Candice L. Schwebel, Rutika Kokate, Daniel M. Geynisman, Matthew R. Zibelman, Pooja Ghatalia, Peter W. Nichols, Woonbok Chung, Jozef Madzo, Noah M. Hahn, David I. Quinn, Jean-Pierre J. Issa, Michael J. Topper, Stephen B. Baylin, Hui Shen, Kerry S. Campbell, Peter A. Jones, Elizabeth R. Plimack
Publikováno v:
Clinical Cancer Research. 29:2052-2065
Purpose: On the basis of preclinical evidence of epigenetic contribution to sensitivity and resistance to immune checkpoint inhibitors (ICI), we hypothesized that guadecitabine (hypomethylating agent) and atezolizumab [anti–programmed cell death li
Autor:
Nizar M. Tannir, Neeraj Agarwal, Camillo Porta, Nicola J. Lawrence, Robert Motzer, Bradley McGregor, Richard J. Lee, Rohit K. Jain, Nancy Davis, Leonard J. Appleman, Oscar Goodman, Walter M. Stadler, Sunil Gandhi, Daniel M. Geynisman, Roberto Iacovelli, Begoña Mellado, Juan Manuel Sepúlveda Sánchez, Robert Figlin, Thomas Powles, Lalith Akella, Keith Orford, Bernard Escudier
Publikováno v:
JAMA oncology. 8(10)
ImportanceDysregulated metabolism is a hallmark of renal cell carcinoma (RCC). Glutaminase is a key enzyme that fuels tumor growth by converting glutamine to glutamate. Telaglenastat is an investigational, first-in-class, selective, oral glutaminase
Autor:
Kevin K Zarrabi, Elizabeth Handorf, Benjamin Miron, Matthew R Zibelman, Fern Anari, Pooja Ghatalia, Elizabeth R Plimack, Daniel M Geynisman
Publikováno v:
The Oncologist. 28:157-164
Background Treatment of metastatic renal cell carcinoma (mRCC) is rapidly evolving with new combination therapies demonstrating improved response rates and survival. There are no head-to-head prospective trials comparing an immunotherapy doublet with
Autor:
Ravi A Madan, Marijo Bilusic, Mark N Stein, Renee N Donahue, Philip M Arlen, Fatima Karzai, Elizabeth Plimack, Yu-Ning Wong, Daniel M Geynisman, Matthew Zibelman, Tina Mayer, Julius Strauss, Gang Chen, Myrna Rauckhorst, Sheri McMahon, Anna Couvillon, Seth Steinberg, William D Figg, William L Dahut, Jeffrey Schlom, James L Gulley
Publikováno v:
Oncologist
Background Before 2018, there was no standard of care for non-metastatic (M0) castration resistant prostate cancer nmCRPC. Androgen receptor antagonists (ARAs) were commonly used sequentially nmCRPC. Methods This was a multicenter, randomized clinica
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f42ae97eefbd0c6b18ed912192756d91
https://europepmc.org/articles/PMC10322134/
https://europepmc.org/articles/PMC10322134/
Publikováno v:
Current Opinion in Urology. 32:495-499
Since the establishment of neoadjuvant chemotherapy as the standard of care for patients with muscle invasive bladder cancer, the pathologic absence of disease, denoted pT0, was found to be predictive of improved overall survival. Accordingly, it has